STEPHEN SAAD

Stephen Saad was born in 1964 in Durban, South Africa. He studied commerce at what is now the University of KwaZulu-Natal and qualified as a chartered accountant — the kind of rigorous financial training that would later make him one of the sharpest dealmakers in African business.

In the early 1990s, he worked in pharmaceutical distribution in KwaZulu-Natal. He learned the mechanics of how drugs move from manufacturer to patient, where the margins sit, and where the system was inefficient.

By 1997, he was ready to build something bigger. He co-founded Aspen Pharmacare Holdings with his cousin Gus Attridge, who became Deputy CEO.

Aspen started as a generic drug manufacturer in South Africa. The early years were spent building production capacity and acquiring product licenses — the rights to manufacture drugs whose patents had expired.

The breakthrough came in 2003 when Aspen acquired a range of products from GlaxoSmithKline. That deal showed the market what Saad was capable of: persuading Big Pharma companies to hand over product rights at prices that left room for Aspen to profit from them.

Similar deals followed with AstraZeneca, Abbott, Novartis, and others. Each deal brought new drugs into the Aspen portfolio and expanded its manufacturing footprint.

By the 2010s, Aspen was making anti-retrovirals for millions of HIV/AIDS patients across sub-Saharan Africa, heparin for European hospitals, and branded pharmaceuticals across multiple therapeutic categories.

During COVID-19, Aspen became the company that manufactured the Johnson and Johnson vaccine under license for distribution across Africa — a moment that demonstrated exactly what Saad had spent two decades building toward: African industrial capacity in pharmaceutical manufacturing at global scale.

Aspen listed on the Johannesburg Stock Exchange and has been one of the JSE's best-performing stocks over multiple decades. Saad remained Group CEO throughout, which is unusual longevity for a company that grew from local to global.

Aspen Pharmacare Holdings is Saad's life's work. Listed on the Johannesburg Stock Exchange (JSE: APN), Aspen manufactures and distributes pharmaceuticals in over 50 countries.

Its product portfolio includes anti-retrovirals used by millions of HIV/AIDS patients in Africa, heparin (a critical blood-thinning medication used in hospitals globally), anesthetics and sterile injectables for surgical settings, and a broad range of branded pharmaceuticals across multiple therapeutic areas.

Aspen's manufacturing sites span South Africa, Australia, Germany, France, Ireland, Brazil, Mexico, and several other countries. This global footprint is rare for an African-founded company and reflects Saad's aggressive acquisition strategy over two decades.

The ARV business is particularly significant. Aspen became one of the world's largest manufacturers of HIV/AIDS drugs, producing them at low cost for distribution across the African continent.

This put Aspen at the center of one of global health's most important supply chains — and gave it enormous scale benefits that competitors couldn't easily match.

During COVID-19, Aspen partnered with Johnson and Johnson to manufacture the J&J COVID-19 vaccine at its Port Elizabeth facility for distribution across Africa. This was both a public health milestone and a demonstration of Aspen's manufacturing capabilities.

Saad is fundamentally an acquirer and a builder. His edge has never been financial engineering or trading — it has been identifying drug products and manufacturing assets that Big Pharma companies no longer wanted, acquiring them for reasonable prices, and then operating them more efficiently than the sellers could.

His approach resembles private equity in its structure — buy something undervalued, improve the operations, generate better returns — but with a much longer time horizon. He doesn't flip assets.

He integrates them, adds manufacturing scale, and holds.

He targets products in therapeutic categories that are essential but not fashionable — blood thinners, anesthetics, generic HIV drugs. These aren't the cancer drugs that attract venture capital and media attention.

But they are drugs that hospitals need to function, which makes demand very predictable and pricing relatively stable.

The GlaxoSmithKline deal in 2003 was the first signal that Saad was operating at a different level. GSK sold Aspen rights to a range of pharmaceutical products — the beginning of a strategy that Saad would repeat with AstraZeneca, Abbott, Novartis, and others.

Each deal brought proven drug rights at prices that gave Aspen room to manufacture profitably.

But the real biggest win is the anti-retroviral portfolio. Aspen became one of the world's largest manufacturers of HIV/AIDS drugs and the dominant supplier to sub-Saharan Africa.

At the HIV/AIDS epidemic's peak, Aspen's drugs were keeping millions of people alive — and the business case was sound. That combination — genuine social impact through a legitimate commercial model — is rare.

The COVID vaccine manufacturing deal with J&J in 2021 is the capstone: it proved that Aspen had built the industrial capacity to manufacture biologics at scale and that Africa had the infrastructure to produce its own vaccines. Saad spent 24 years building toward that capability without ever describing it in those terms.

Aspen's debt-fueled expansion into European sterile injectables in the mid-2010s created the most dangerous period in the company's history. Saad made several large acquisitions in Europe — particularly in anesthetics and sterile injectables — at prices that left Aspen with a debt load that the market eventually lost patience with.

By 2018-2019, Aspen's share price had fallen more than 60% from its peak as investors worried about the company's ability to service its debt and questioned whether the European division would ever generate the returns the acquisitions implied. Some analysts speculated about a debt spiral.

Saad responded by divesting assets, restructuring the portfolio, and cutting costs. The company stabilized and recovered.

But the episode was a reminder that even the best dealmakers can overpay and over-expand. Aspen's European ambitions were right in direction but expensive in execution.

Saad's philosophy is rooted in manufacturing economics. He understands the difference between a business that creates genuine industrial value — making something that people need — and a business that is just moving money around.

He chose to build the former.

His core belief is that Africa needs its own pharmaceutical manufacturing capability. Dependence on imported drugs is expensive, fragile, and leaves African healthcare systems vulnerable to supply disruptions.

He set out to change that — not as a charity, but as a profitable business. The COVID-19 pandemic proved exactly how right he was.

On acquisitions, he thinks in terms of portfolio optionality: each product license adds to the manufacturing base, and manufacturing scale lowers the cost of every new product. The bigger the manufacturing base, the cheaper each incremental product becomes to add.

That compounding logic has driven Aspen's growth strategy for 25 years.

Saad is married to Tracey Saad and they have children together. They live in Durban, KwaZulu-Natal, where Saad has built his entire career.

His family life is private — consistent with his general preference for keeping a low public profile outside of business contexts.

His professional relationship with his cousin Gus Attridge — Aspen's co-founder and Deputy CEO — is one of the defining features of his story. They have built the company together for over 25 years, which is an extraordinary partnership by any measure.

Family is not just background for Saad — it is woven into the founding structure of his business.

Saad studied commerce at what is now the University of KwaZulu-Natal in Durban and qualified as a chartered accountant. That CA training gave him the financial discipline and analytical rigor that shows up in how Aspen structures acquisitions and manages its balance sheet.

He did not study at an international business school or accumulate fancy credentials — he built the world-class business first.

As an Amazon Associate, Netfigo earns from qualifying purchases. Book links above may be affiliate links.